Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
2seventy bio (TSVT)
NASDAQ:TSVT
Holding TSVT?
Track your performance easily
TSVT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.92 - $6.40
Previous Close$3.99
Volume92.98K
Average Volume (3M)308.89K
Market Cap
$205.84M
Enterprise Value$260.88M
Total Cash (Recent Filing)$192.40M
Total Debt (Recent Filing)$247.45M
Price to Earnings (P/E)―
Beta3.06
Next Earnings
Mar 25, 2025EPS Estimate
-$0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.85
Shares Outstanding51,588,420
10 Day Avg. Volume406,635
30 Day Avg. Volume308,895
Standard Deviation0.30
R-Squared0.09
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.70
Price to Sales (P/S)3.64
Price to Cash Flow (P/CF)-4.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.77
Enterprise Value/Gross Profit3.13
Enterprise Value/Ebitda-1.89
Forecast
1Y Price Target
$4.00Price Target Upside0.25% Upside
Rating ConsensusHold
Number of Analyst Covering4
2seventy bio News
PremiumCompany Announcements
2seventy bio Reports Strong Growth in Abecma Sales
PremiumCompany Announcements
2seventy bio Reports Strong Q3 with Abecma Growth
PremiumCompany Announcements
2seventy bio Halts KarMMa-9 Study, Forecasts Strong Abecma Sales
Bulls Say, Bears Say
Bulls Say
Earnings2Seventy Bio, Inc. reported $11M in Q3 Abecma collaborative arrangement revenue, showing a significant 150% quarter-over-quarter increase.
Financial PerformanceManagement guided to ~30% quarter-over-quarter U.S. sales growth, which implies above consensus performance.
Market PositionAbecma can ramp up to a steady, and profitable, position in 3L+ relapsed / refractory multiple myeloma based on differentiated safety and consistent real-world efficacy.
Bears Say
Market Position And Future ProspectsLong-term prospects for Abecma remain unclear due to competition from superior efficacy treatments and survey results indicating limited change in outlook for Abecma.
Product Development And Market InterestThe KarMMa-9 study will be discontinued due to slower than expected enrollment.
Sales And CompetitionQ4 sales are expected to be impacted by continued competition and a reduction in CAR-T infusions during the US holiday season.
---
Ownership Overview
10.15% Insiders
10.76% Mutual Funds
42.40% Other Institutional Investors
23.63% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TSVT FAQ
What was 2seventy bio’s price range in the past 12 months?
2seventy bio lowest stock price was $1.92 and its highest was $6.40 in the past 12 months.
What is 2seventy bio’s market cap?
Currently, no data Available
When is 2seventy bio’s upcoming earnings report date?
2seventy bio’s upcoming earnings report date is Mar 25, 2025 which is in 93 days.
How were 2seventy bio’s earnings last quarter?
2seventy bio released its earnings results on Nov 12, 2024. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.193 by $0.003.
Is 2seventy bio overvalued?
According to Wall Street analysts 2seventy bio’s price is currently Undervalued.
Does 2seventy bio pay dividends?
2seventy bio does not currently pay dividends.
What is 2seventy bio’s EPS estimate?
2seventy bio’s EPS estimate is -$0.11.
How many shares outstanding does 2seventy bio have?
2seventy bio has 51,588,420 shares outstanding.
What happened to 2seventy bio’s price movement after its last earnings report?
2seventy bio reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.193. Following the earnings report the stock price went down -6.957%.
Which hedge fund is a major shareholder of 2seventy bio?
Among the largest hedge funds holding 2seventy bio’s share is Baker Bros Advisors LP. It holds 2seventy bio’s shares valued at 12M.
---
2seventy bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.00 (0.25% Upside)
$4.00 (0.25% Upside)
Blogger Sentiment
Bullish
TSVT Sentiment 75%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 268.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $18.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 8.8%
Last 30 Days ▼ 8.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
107.81%
12-Months-Change
Fundamentals
Return on Equity
-35.38%
Trailing 12-Months
Asset Growth
-21.37%
Trailing 12-Months
Company Description
2seventy bio
2seventy bio Inc is primarely in the business of pharmaceutical preparations.
---
TSVT Earnings Call
Q3 2024
0:00 / 0:00
---
TSVT Stock 12 Month Forecast
Average Price Target
$4.00
▲(0.25% Upside)
Technical Analysis
Best Analysts Covering TSVT
1 Year
1 Year Success Rate
0/20 ratings generated profit
1 Year Average Return
-43.01%
reiterated a buy rating 2 months ago
Copying Daina Graybosch's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -43.01% per trade.
---